J Korean Assoc Oral Maxillofac Surg.  2010 Oct;36(5):341-345.

Evaluation of osteogenic activity of periosteal-derived cells treated with inflammatory cytokines

• Park BW
• Choi MJ
• Hah YS
• Cho HY
• Kim DR
• Kim UK
• Kang HJ
• Kim JR
• Byun JH

Abstract

INTRODUCTION
Skeletal homeostasis is normally maintained by the stability between bone formation by osteoblasts and bone resorption by osteoclasts. However, the correlation between the inflammatory reaction and osteoblastic differentiation of cultured osteoprogenitor cells has not been fully investigated. This study examined the effects of inflammatory cytokines on the osteoblastic differentiation of cultured human periosteal-derived cells.
MATERIALS AND METHODS
Periosteal-derived cells were obtained from the mandibular periosteum and introduced into the cell culture. After passage 3, the periosteal-derived cells were further cultured in an osteogenic induction Dulbecco's modified Eagle's medium (DMEM) medium containing dexamethasone, ascorbic acid, and beta-glycerophosphate. In this culture medium, tumor necrosis factor (TNF)-alpha with different concentrations (0.1, 1, and 10 ng/mL) or interleukin (IL)-1beta with different concentrations (0.01, 0.1, and 1 ng/mL) were added.
RESULTS
Both TNF-alpha and IL-1beta stimulated alkaline phosphatase (ALP) expression in the periosteal-derived cells. TNF-alpha and IL-1beta increased the level of ALP expression in a dose-dependent manner. Both TNF-alpha and IL-1beta also increased the level of alizarin red S staining in a dose-dependent manner during osteoblastic differentiation of cultured human periosteal-derived cells.
CONCLUSION
These results suggest that inflammatory cytokines TNF-alpha and IL-1beta can stimulate the osteoblastic activity of cultured human periosteal-derived cells.

Keyword

Periosteal-derived cells; Inflammatory cytokine; Tumor necrosis factor-alpha (TNF-alpha); Interleukin-1beta (IL-1beta)

MeSH Terms

Alkaline Phosphatase
Anthraquinones
Ascorbic Acid
Bone Resorption
Cell Culture Techniques
Cytokines
Dexamethasone
Durapatite
Glycerophosphates
Homeostasis
Humans
Interleukins
Osteoblasts
Osteoclasts
Osteogenesis
Periosteum
Tumor Necrosis Factor-alpha
Alkaline Phosphatase
Anthraquinones
Ascorbic Acid
Cytokines
Dexamethasone
Durapatite
Glycerophosphates
Interleukins
Tumor Necrosis Factor-alpha

Figure

• 

  Fig. 1. ALP expression in the periosteal-derived cells treated with TNF-αat 3 days of culture. A. No treatment of TNF-α. B. Treatment of 0.1 ng/mL TNF-α. C. Treatment of 1 ng/mL TNF-α. D. Treatment of 10 ng/mL TNF-α. (ALP: alkaline phosphatase, TNF: tumor necrosis factor)

• 

  Fig. 2. ALP expression in the periosteal-derived cells treated with IL-1βat 3 days of culture. A. Treatment of 0.01 ng/mL IL-1β. B. Treatment of 0.1 ng/mL IL-1β. C. Treatment of 1 ng/mL IL-1β. (ALP: alkaline phosphatase, IL: interleukin)

• 

  Fig. 3. Alizarin red S staining for mineralized nodule formation in periosteal-derived cells treated with 0.1, 1, and 10 ng/mL TNF-α or 0.01, 0.1, and 1 ng/mL IL-1β. (TNF: tumor necrosis factor, IL: interleukin, OM-; non-osteogenic induction medium, OM+; osteogenic induction medium)

• 

  Fig. 4. Quantification of alizarin red S in periosteal-derived cells treated with 0.1, 1, and 10 ng/mL TNF-α or 0.01, 0.1, and 1 ng/mL IL-1β. (TNF: tumor necrosis factor, IL: interleukin, OM-; nonosteogenic induction medium, OM+; osteogenic induction medium)

Reference

References

12. Park BW, Byun JH, Lee SG, Hah YS, Kim DR, Cho YC, et al. Evaluation of osteogenic activity and mineralization of cultured human periosteal-derived cells. J Korean Assoc Maxillofac Plast Reconstr Surg. 2006; 28:511–9.

13. Park BW, Byun JH, Ryu YM, Hah YS, Kim DR, Cho YC, et al. Correlation between vascular endothelial growth factor signaling and mineralization during osteoblastic differentiation of cultured human periosteal-derived cells. J Korean Assoc Maxillofac Plast Reconstr Surg. 2007; 29:197–205.

14. Walsh NC, Gravallese EM. Bone remodeling in rheumatic disease: a question of balance. Immunol Rev. 2010; 233:301–12.

15. Li YP, Stashenko P. Proinflammatory cytokines tumor necrosis factoralpha and IL-6, but not IL-1, downregulate the osteocalcin gene promoter. J Immunol. 1992; 148:788–94.

16. Panagakos FS, Hinojosa LP, Kumar S. Formation and mineralization of extracellular matrix secreted by an immortal human osteoblastic cell line: modulation by tumor necrosis factoralpha. Inflammation. 1994; 18:267–84.

17. Nanes MS. Tumor necrosis factoralpha: molecular and cellular mechanisms in skeletal pathology. Gene. 2003; 321:1–15.

18. Segal B, Rhodus NL, Patel K. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008; 106:778–87.

19. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med. 2002; 196:77–85.

20. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005; 115:282–90.

21. Zwerina J, Redlich K, Polzer K, Joosten L, Kro¨nke G, Distler J. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA. 2007; 104:11742–7.